Data as of Apr 15
| -0.89 / -0.67%|
Illumina, Inc. develops, manufactures and markets life science tools and integrated systems for the analysis of genetic variation and function. It provides a comprehensive line of genetic analysis solutions with products and services that serve a broad range of highly interconnected markets, including sequencing, genotyping, gene expression and molecular diagnostics. The company operates its business through two segments: Life Sciences Business unit and Diagnostics Business unit. The Life Sciences Business unit includes all products and services related to the research market, namely the product lines based on its sequencing, bead-array, vera-code, and real-time PCR technologies. The Diagnostics Business unit focuses on the emerging opportunity in molecular diagnostics. Its customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. The company's broad portfolio of systems, consumables, and analysis tools are designed to simplify genetic analysis that addresses a full range of genomic complexity, price points, and throughputs, enabling researchers to select the best solution for their scientific challenge. Illumina was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
|Jay T. Flatley||Chief Executive Officer & Director|
|Francis A. deSouza||President & Director|
|William Bonnar||Senior Vice President-Operations|
|Marc A. Stapley||Chief Financial Officer & Senior Vice President|
|Mostafa Ronaghi||Chief Technology Officer & Senior Vice President|